Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01527838 · ClinicalTrials.gov registry record · Phase 1
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
A Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Hodgkin's Disease, sponsored by Fate Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT01527838 is a Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Hodgkin's Disease that has completed, run by Fate Therapeutics. The registered enrollment target is 10 participants, below the 191-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT01527838, a Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Hodgkin's Disease, has completed, sponsored by Fate Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
This trial is a prospective, open-label, single-arm trial of the safety of a single FT1050-treated CB unit for hematopoietic reconstitution after a reduced-intensity conditioning regimen for hematologic malignancies. A maximum of 40 eligible adult subjects will be enrolled and treated in the trial at approximately 2-4 centers within the U.S.
Conditions Studied
Interventions
- BIOLOGICAL Single FT1050 treated UCB unit
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program - Boston
Ohio
- Ohio State Univeristy Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01527838
The ClinicalTrials.gov registry entry for NCT01527838 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 191-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (95% lower). The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 1 intervention - of which Single FT1050 treated UCB unit is the first listed.
NCT01527838 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT01527838 about?
NCT01527838 is a clinical study titled "Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit". This trial is a prospective, open-label, single-arm trial of the safety of a single FT1050-treated CB unit for hematopoietic reconstitution after a reduced-intensity conditioning regimen for hematologic malignancies. A maximum of 40 eligible adult subjects will be enrolled and treated in the trial a...
What is the current status of trial NCT01527838?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2012-01. Estimated completion is 2013-11.
What conditions does trial NCT01527838 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Hodgkin's Disease, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Non-Hodgkins Lymphoma (NHL).
What interventions are being tested in trial NCT01527838?
The interventions under investigation include: Single FT1050 treated UCB unit (BIOLOGICAL).
Who is sponsoring clinical trial NCT01527838?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01527838 being conducted?
This trial has 3 study locations across Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
RECRUITING · Phase 1
-
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
ACTIVE NOT RECRUITING · Phase 1
-
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Chronic Lymphocytic Leukemia (CLL)
All registered trials for this condition
Hodgkin's Disease
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.